公开(公告)号：US20230357378A1

公开(公告)日：2023-11-09

申请号：US18301803

申请日：2023-04-17

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Dong Sik KIM ,  Soon-gu KWON

IPC: C07K16/24 ,  A61P25/02

CPC classification number: C07K16/24 ,  A61P25/02 ,  A61K45/06

Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.

公开(公告)号：US11560425B2

公开(公告)日：2023-01-24

申请号：US16626625

申请日：2018-06-27

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol Kim ,  Eun Bee Cho ,  Dong Sik Kim ,  Jae-Keun Lee ,  Soon-gu Kwon ,  Jae Young Seong ,  Juwon Shim ,  Tae Woo Kim ,  Shin-hyuk Kang

IPC: C07K16/24 ,  C07K16/30 ,  A61P35/00 ,  A61K45/06 ,  A61K39/00 ,  C07K16/28 ,  A61K39/395

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.

公开(公告)号：US11332521B2

公开(公告)日：2022-05-17

申请号：US16348058

申请日：2017-11-07

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Bongcheol Kim ,  Jae Young Seong ,  Jong Ik Hwang ,  Eun Bee Cho ,  Junho Chung ,  Junyeong Jin ,  Tae Young Yune ,  Jee Youn Lee

IPC: C07K16/18 ,  C07K7/00 ,  A61K39/00 ,  G01N33/563

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.

公开(公告)号：US20200157202A1

公开(公告)日：2020-05-21

申请号：US16626630

申请日：2018-06-27

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Dong Sik KIM ,  Soon-gu KWON

IPC: C07K16/24

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.

公开(公告)号：US20200010509A1

公开(公告)日：2020-01-09

申请号：US16511976

申请日：2019-07-15

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Jae Young SEONG ,  Jong-Ik HWANG ,  Dong-Hoon KIM ,  Gi Hoon SON ,  Yoo-Na LEE ,  Seongsik YUN ,  Arfaxad REYES-ALCARAZ

IPC: C07K7/08 ,  A61K9/19 ,  A61K9/00 ,  A61P25/06 ,  A61P25/24 ,  A61P25/18 ,  A61P25/22 ,  A61P25/30 ,  A61P25/28

Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.

公开(公告)号：US12072339B2

公开(公告)日：2024-08-27

申请号：US16753295

申请日：2018-10-02

Applicant: Neuracle Science Co., Ltd.

Inventor： Jae Young Seong ,  Byung Joo Ham ,  Min-Hyeok Lee ,  Nui Ha

IPC: G01N33/68 ,  C07K16/24 ,  C12Q1/6883

CPC classification number: G01N33/6896 ,  C07K16/24 ,  C12Q1/6883 ,  C07K2317/622 ,  C12Q2600/158 ,  G01N2800/304

Abstract: The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.

公开(公告)号：US20240175880A1

公开(公告)日：2024-05-30

申请号：US18552293

申请日：2022-11-23

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Jae Young SEONG ,  Hoyun KWAK ,  Sitaek OH ,  Min-Hyeok LEE

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/28 ,  G01N2800/52

Abstract: The present disclosure relates to the use of LRRC4 family mimic molecules to determine the expression level of FAM19A5 protein in a subject. In some aspects, such mimic molecules can be used to identify and/or diagnose a subject suffering from or at risk of developing a disease or disorder associated with increased FAM19A5 protein expression. The present disclosure also provides methods of treating subjects identified and/or diagnosed using the methods provided herein.

公开(公告)号：US11618783B2

公开(公告)日：2023-04-04

申请号：US16626624

申请日：2018-06-27

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol Kim ,  Jae-Keun Lee ,  Dong Sik Kim ,  Junho Chung ,  Junyeong Jin

IPC: C07K16/00 ,  A61K39/395 ,  C07K16/24 ,  A61P35/00 ,  G01N33/50 ,  G01N33/574 ,  A61K39/00

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.

公开(公告)号：US20210388382A1

公开(公告)日：2021-12-16

申请号：US17053733

申请日：2019-05-08

Applicant: Neuracle Science Co., Ltd. ,  Neuracle Genetics

Inventor： Jong-Mook KIM ,  Dong Sik KIM ,  Juwon SHIM ,  Soon-gu KWON

IPC: C12N15/86 ,  C07K16/24

Abstract: The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.

公开(公告)号：US11155613B2

公开(公告)日：2021-10-26

申请号：US16626621

申请日：2018-06-27

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol Kim ,  Jae-Keun Lee ,  Dong Sik Kim

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/24 ,  G01N33/68

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.